BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
FDMT upcoming catalysts
4D Molecular Therapeutics: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 0 FDA event(s). Subscribe to FDMT (.ics).
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|
| No upcoming PDUFA date or AdCom found. |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| No trials in this window. |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|
| No FDA decision events in this window. |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-06 est. | P1/P2 | 4D Molecular Therapeutics FDMT | NCT05629559 4D-310 in Adults With Fabry Disease and Cardiac Involvement | Fabry Disease | recruiting | 18 |
| 2026-06 est. | P1/P2 | 4D Molecular Therapeutics FDMT | NCT04517149 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) | X-Linked Retinitis Pigmentosa | active not recruiting | 21 |
| 2026-01 est. | P1/P2 | 4D Molecular Therapeutics FDMT | NCT04519749 An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease | Fabry Disease | active not recruiting | 18 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.